Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial

被引：0
|
作者：
Wang, J-S. [1 ]
Wu, T. [1 ]
Hong, Y-G. [1 ]
Guo, Y-Z. [2 ]
Luo, S-X. [3 ]
Li, N. [3 ]
Cheng, Y-F. [4 ]
Li, B-S. [5 ]
机构：
[1] Anyang Tumour Hosp, Dept Med Oncol, Anyang, Peoples R China
[2] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Med Oncol, Luoyang, Peoples R China
[3] Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[4] Shandong Univ, Qilu Hosp, Dept Radiat Oncol, Jinan, Peoples R China
[5] Shandong Canc Hosp, Dept Radiat Oncol, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1954
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1448P
引用
收藏
页码：S910 / S911
页数：2
相关论文
共 50 条
  • [1] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase II clinical trial.
    Wang Junsheng
    Luo Suxia
    Li Ning
    Wu Tao
    Hong Yonggui
    Guo Yanzhen
    Cheng Yufeng
    Li Baosheng
    Tan Bingxu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Qin, Yan-ru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 340 - 340
  • [3] Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Zhang, Yan-Feng
    Hao, An-Lin
    Hong, Yong-Gui
    Li, Xiao-Ming
    Liang, Wei-Min
    Zheng, Zhi-Xin
    Yang, Guang-Yi
    Guo, Xiao-Feng
    Wen, Yan-Yan
    Cao, Heng
    Le, Cheng
    Song, Hua-Jie
    Su, Wen-Zhong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16015 - E16015
  • [4] Update results of anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Zhang, Y-F.
    Li, X-B.
    Hong, Y-G.
    Li, X-M.
    Liang, W-M.
    Zheng, Z-X.
    Yang, G-Y.
    Wen, Y-Y.
    Cao, H.
    Wu, W-L.
    Su, W-Z.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1120 - S1120
  • [5] Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Jia, Yong-Xu
    Yan, Jie
    Qin, Yanru
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial.
    Wang, Junsheng
    Wu, Tao
    Luo, Suxia
    Li, Ning
    Hong, Yonggui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial
    Wang, J.
    Wu, T.
    Hong, Y-G.
    Luo, S-X.
    Li, N.
    Guo, Y-Z.
    Cheng, Y-F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1058 - S1058
  • [8] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Wang, Junsheng
    Wu, Tao
    Luo, Suxia
    Li, Ning
    Hong, Yonggui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Li, Ning
    Wu, Tao
    Hong, Yong-Gui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Wang, Junsheng
    Luo, Suxia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 376 - 376
  • [10] TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase. trial
    Wang, Junsheng
    Li, Ning
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Luo, Su-xia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345